What should you know about mirvetuximab soravtansine ovarian cancer?

This medicine is an antibody-drug conjugate. Its antibody attaches to a marker on some cancer cells and carries a cell-killing medicine into the tumour cell. It is not suitable for every ovarian cancer, so the pathology team may review tumour features before treatment.

Your care plan may also include imaging, surgery, chemotherapy, or supportive care depending on the cancer’s extent, previous treatment, general health, and goals. Ovarian cancer information can help place this discussion in context.

Ask which tumour marker was found, how the result was measured, and why this medicine is preferred for your situation. Tell the team about eye problems, breathing conditions, liver problems, allergies, and every medicine or supplement you use.

Eye checks and protective instructions may be part of care because eye irritation or vision changes can occur. Follow the clinic’s instructions about eye drops and contact lenses, and report new visual symptoms early. Do not drive if your vision is affected.

Contact the oncology team promptly for blurred vision, eye pain, light sensitivity, worsening cough, breathlessness, fever, or severe weakness. Seek urgent help for severe breathing difficulty, facial swelling, or a sudden major change in vision. Early reporting allows the team to assess whether treatment needs adjustment.

Ask whether your tumour has the marker needed for treatment, what testing was used, how eye health will be monitored, which alternatives exist, and how this medicine fits with chemotherapy or surgery. Ask who to contact outside clinic hours.